Alprostadil
- Atc Codes:C01EA01#G04BE01
- CAS Codes:745-65-3
- PHARMGKB ID:745-65-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Alprostadil, Alprostapint, Caverject, Minprog, Muse, Pridax; Belgium: Caverject, Prostin; Bulgaria: Alprostapint, Prostavasin; Cyprus: Caverject; Czech Republic: Alprestil, Alprostan, Alprostapint, Caverject, Karon, Muse, Prostavasin; Denmark: Caverject, Muse, Prostivas; Estonia: Caverject, Muse, Vasostenoon; Finland: Caverject, Muse, Prostivas; France: Caverject, Edex, Muse, Prostine VR; Germany: Caverject, Minprog, Muse, Prostavasin, Viridal; Greece: Caverject, Muse, Prostin; Hungary: Alprestil, Alprobotal, Alprostadil, Caverject, Prostavasin, Prostin; Ireland: Caverject, Muse, Viridal; Italy: Alprostar, Caverject, Muse, Prostavasin, Prostin; Latvia: Caverject, Muse, Vasaprostan, Vasostenoon; Lithuania: Muse, Vasaprostan; Luxembourg: Caverject, Muse, Prostavasin; Netherlands: Prostin, Muse; Poland: Alprostapint, Caverject, Muse, Prostavasin, Prostin; Portugal: Caverject, Muse, Prostin, Vasoprost; Romania: Alprostadil, Pridax, Vasaprostan; Slovakia: Prostavasin, Alprostapint, Alprostan, Slovenia: Alprostin, Caverject, Spain: Alprostadil, Caverject; Sweden: Bondil, Caverject, Prostivas; UK: Caverject, Muse, Prostin, Viridal.
North America
Canada: Alprostadil, Caverject, Muse, Prostin; USA: Alprostadil, Caverject, Edex, Muse, Prostin.
Latin America
Argentina: Alprostadil, Cardiobrón, Prolisina, Prostavasin; Brazil: Aplicav, Caverject, Prostavasin; Mexico: Caverject.
Asia
Japan: Altesil, Alyprost, Apistandin, Ipceryl, Liple, Mediprost, Palux, Prink, Prostandin, Tandetron.
Drug combinations
Chemistry
Alprostadil: C~20~H~34~O~5~. Mw: 354.48. (1) Prost-13-en-1-oic acid,11,15-dihydroxy-9-oxo-;(11α,13E,15S)-; (2)(1R,2R,3R)-3-Hydroxy-2-[(E)-(3S)-3-hydroxy-1-octenyl]-5-oxocyclopentaneheptanoic acid. CAS-745-65-3 (1977).
Pharmacologic Category
Vasodilating Agents, Miscellaneous; Prostaglandin. (ATC-Code: C01EA01; G04BE01; G04BE01).
Mechanism of action
Vasodilation on vascular and ductus arteriosus smooth muscle. Relaxation of trabecular smooth muscle in penile cavernosal arteries.
Therapeutic use
Congenital heart defects in neonates, including ductus arteriosus, pulmonary atresia, pulmonary stenosis, tricuspid atresia, Fallot’s tetralogy, transposition of the great vessels, interruption of aortic arch, coarctation of aorta, hypoplastic left ventricle. Treatment of erectile dysfunction.
Pregnancy and lactiation implications
Unlabeled use
Investigational: Treatment of pulmonary hypertension in infants and children with congenital heart defects with left-to-right shunts.
Contraindications
Hypersensitivity to alprostadil or any component of the formulation. Hyaline membrane disease or persistent fetal circulation. Respiratory distress syndrome. Conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia). Anatomical deformation of the penis. Penile implants.
Warnings and precautions
Apnea may occur in neonates with congenital heart defects (especially in those weighing <2 kg at birth). Priapism may occur when used in erectile dysfunction. Use with caution in neonates with bleeding tendencies.